login
  Password reminder
NeuroNews
Contact the editor Visit NeuroNews Twitter feed Visit NeuroNews Facebook page
 

Preliminary results of laser ablation promising for inoperable brain tumours and epilepsy


Friday, 30 Aug 2013 15:05
Laser catheter insertion
Laser catheter insertion

“The results of laser ablation to treat inoperable brain tumours, epilepsy and refractory cancer pain are very exciting,” Shabbar F Danish, director, Stereotactic and Functional Neurosurgery and assistant professor at Rutgers-Robert Wood Johnson Medical School and Robert Wood Johnson University Hospital, New Brunswick, USA, told NeuroNews.


What are the preliminary results of laser ablation performed on patients at Robert Wood Johnson?

We have performed over 100 laser procedures to date. The preliminary results are very exciting as we are able to achieve outcomes similar to open procedures without the side-effects of an open procedure in many types of cases.

 

What is the evidence in the literature for use of laser ablation for epilepsy?

Ablation techniques have been used to treat brain tumours for many years, starting in the late 1980s. The use for epilepsy is fairly new, being introduced in 2010. We are just starting to see this data in the literature for epilepsy. This year will mark the beginning of the first national multicentre trial to understand the efficacy of laser therapy in the treatment of temporal lobe epilepsy.

Alternative treatments for brain tumour patients include chemotherapies, radiation therapies, and open surgery. The traditional treatment for refractory epilepsy involves an open craniotomy. This procedure aims to achieve the same outcome without having the patients undergo an open operation.

What improvements do patients see after the procedure?

It depends on the type of disease being treated. For patients with brain tumours, we are able to get the tumours to stop growing. For epilepsy patients, we are able to cure their seizures and patients become seizure free. There are some tumours that we have been able to cure, and others that require a repeat treatment to keep them under control. Tumour growth is monitored with close imaging, and recurrence is objectified via analysis by a multidisciplinary neuro-oncology board. Outcomes for epilepsy patients are monitored using the Engel classification system. Patients treated for refractory pain syndromes are monitored using the brief pain inventory (BPI)-short form.

 

What type of patient is the suitable candidate for laser ablation?

Patients diagnosed with any type of brain tumour who have been told they do not have other options, patients with epilepsy that has not responded to medications, and patients with cancer-related pain may be candidates for laser ablation. In addition, patients who have had CyberKnife or gamma knife surgery for a brain tumour that then grows back are very good candidates for this therapy.

 

What are the complications associated with laser ablation?

Complications associated with the procedure include a 1% risk of haemorrhage or stroke. There is a 2–5% chance that the laser is not placed in an optimal position and there is a risk that the tumour or epilepsy focus is not completely ablated. In the latter case, the procedure can be repeated.

 

What is your message to other neurointerventionists?

I think that it is important to consider a minimally invasive option when it exists. The open or more risky alternative is always an option, but as we have learned from other specialties in medicine, if we can achieve the same outcomes with a minimally invasive procedure, why would we not take that approach?

 

Do you involve other specialties in case selection?

We approach all patients through a multidisciplinary board and when this approach is not appropriate will recommend alternative strategies. We believe that all patients and physicians should be educated about all the options that exist, especially if one is available that affords the patients less morbidity from the procedure.




Add New Comment

Related Items


Most popular


MR CLEAN: Better outcomes with intervention in ischaemic stroke patients
Thursday, 18 Dec 2014
For the first time, the Multicentre randomised clinical trial of endovascular treatment for acute ischaemic stroke in the Netherlands (MR CLEAN) has shown better outcomes in favour of intervention in ... MR CLEAN: Better outcomes with intervention in ischaemic stroke patients

Medtronic completes acquisition of Covidien
Tuesday, 27 Jan 2015
Under the terms of the acquisition agreement, Medtronic Inc and Covidien plc are now combined under Medtronic plc. Medtronic completes acquisition of Covidien

PulseRider safe and effective in early USA experience
Thursday, 08 Jan 2015
Initial experience with PulseRider (Pulsar Vascular) has shown the device to be safe and effective as an adjunct in the treatment of bifurcation aneurysms arising at the basilar apex or carotid ... PulseRider safe and effective in early USA experience

Features


TeleStroke Units improve stroke care in underserved areas
Wednesday, 07 Jan 2015
Peter Müller-Barna writes that the use of telemedicine to ensure 24/7 access to consultation and care in rural areas is one of the major recommendations of the American Stroke Association in their ... TeleStroke Units improve stroke care in underserved areas

Impact“ful” moments
Friday, 05 Dec 2014
Once a year, in almost ritualised fashion, the editors of peer-reviewed journals anxiously await publication of the Thomson Reuters Impact Factor. Journals in the “neuro” space are no exception to ... Impact“ful” moments

Profiles


Joseph Broderick
Wednesday, 07 Jan 2015
Joseph Broderick speaks to NeuroNews about the future of neurology and his research, in particular, ... Joseph Broderick

Vladimír Beneš Jr
Tuesday, 30 Sep 2014
Vladimír Beneš Jr is professor and chair at the First Medical School, Charles University, P... Vladimír Beneš Jr

Cardiac Rhythm News Vascular News Cardiovascular News Interventional News Spinal News NeuroNews
BIBA Medical BIBA MedTech Insights CX Symposium ilegx
 
Password Reminder

BIBA Medical, 526 Fulham Road, Fulham, London, SW6 5NR.
TEL: +44 (0)20 7736 8788 FAX: +44 (0)20 7736 8283 EMAIL: 
info@bibamedical.com
© BIBA Medical Ltd is a company registered in England and Wales with company number 2944429.
VAT registration number 730 6811 50.
Site Map | Terms and Conditions